Ascentage Pharma Group International

5 days ago · defenseworld.net

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $15.40 and last traded at $15.1410, with a volume of 3803 shares trading hands. The stock had previously closed at $16.00. Wall Street Analyst

1 month ago · seekingalpha.com

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.

1 month ago · globenewswire.com

Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.

2 months ago · globenewswire.com

In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in the first paragraph of the release, the time should be 7:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 7:00 pm Hong Kong Time (HKT) and not 9 am EDT and 9 pm HKT as previously stated. The corrected release follows:

2 months ago · globenewswire.com

ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 9:00 pm Hong Kong Time (HKT) on August 19, 2026.

2 months ago · globenewswire.com

ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced the appointment of Faiçal Miyara, PhD, as Chief Business Officer (CBO), responsible for the Company's global business development, and Jim Ziegler as Chief Commercial Officer (CCO), responsible for the commercialization of the Company's products in the United States and other countries outside of China.

2 months ago · zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 160.1% in Ascentage Pharma Group International - Unsponsored ADR (AAPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

2 months ago · globenewswire.com

ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that its Chairman and Chief Executive Officer, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No.

2 months ago · zacks.com

The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group International - Unsponsored ADR (AAPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.